Hepatitis C: Drug Development Pipeline Study, H2 2018
With an estimated market value of over $30 billion by 2020, the Hepatitis C industry is considered as the rapidly growing healthcare markets. Hepatitis C affects around 200 million people worldwide and is associated with highest treatment failure rates. Currently, no vaccine is available against HCV. Due to the mutations in Hepatitis C virus, development of a prophylactic vaccine is highly challenging.
The condition is classified into 6 genotypes, of which GT-1 genotype is the most prevalent. The condition is a contagious liver disease which can be either acute or chronic. It can rapidly progress into serious liver problems including cirrhosis or liver cancer.
Hepatitis C pipeline comprises of 85 active drugs under active development as of June 2018. Of these, 16 drugs are in Phase 1 and 19 drugs in phase 2. Only 4 drugs progressed to Phase 3. Further, 27 drugs are in Pre-clinical stage, 18 drugs in research/discovery stages.
60 companies are developing the pipeline for Hepatitis C. Of this, GinkgoPharma Co. Ltd, Biocad CJSC, Cocrystal Pharma Inc, ARA Healthcare Pvt Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Beijing Kawin Technology Share-Holding Co., Ltd. and Achillion Pharmaceuticals, Inc. have more compounds in pipeline. On the other hand, Presidio Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd, Ascletis, Inc. and Beijing Kawin Technology Share-Holding Co., Ltd. have most advanced pipeline products.
Mechanism of Action of most of the therapeutic candidates is HCV NS5A Inhibitors, Immunostimulants and Immunomodulators.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Hepatitis C (HCV) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Hepatitis C (HCV) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Hepatitis C (HCV) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
The condition is classified into 6 genotypes, of which GT-1 genotype is the most prevalent. The condition is a contagious liver disease which can be either acute or chronic. It can rapidly progress into serious liver problems including cirrhosis or liver cancer.
Hepatitis C pipeline comprises of 85 active drugs under active development as of June 2018. Of these, 16 drugs are in Phase 1 and 19 drugs in phase 2. Only 4 drugs progressed to Phase 3. Further, 27 drugs are in Pre-clinical stage, 18 drugs in research/discovery stages.
60 companies are developing the pipeline for Hepatitis C. Of this, GinkgoPharma Co. Ltd, Biocad CJSC, Cocrystal Pharma Inc, ARA Healthcare Pvt Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Beijing Kawin Technology Share-Holding Co., Ltd. and Achillion Pharmaceuticals, Inc. have more compounds in pipeline. On the other hand, Presidio Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd, Ascletis, Inc. and Beijing Kawin Technology Share-Holding Co., Ltd. have most advanced pipeline products.
Mechanism of Action of most of the therapeutic candidates is HCV NS5A Inhibitors, Immunostimulants and Immunomodulators.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Hepatitis C (HCV) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Hepatitis C (HCV) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Hepatitis C (HCV) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 HEPATITIS C- COMPANY WISE PIPELINE ANALYSIS
3.1 AKSHAYA BIO INC. PIPELINE, H1 2018
3.2 ALLACHEM, LLC PIPELINE, H1 2018
3.3 AMARNA THERAPEUTICS BV PIPELINE, H1 2018
3.4 ARA HEALTHCARE PVT LTD PIPELINE, H1 2018
3.5 ASCLETIS, INC PIPELINE, H1 2018
3.6 ATEA PHARMACEUTICALS, INC PIPELINE, H1 2018
3.7 BEIJING KAWIN TECHNOLOGY PIPELINE, H1 2018
3.8 BETA PHARMA, INC PIPELINE, H1 2018
3.9 BIOCAD CJSC PIPELINE, H1 2018
3.10 BIOTRON LIMITED PIPELINE, H1 2018
3.11 BOLDER BIOTECHNOLOGY, INC PIPELINE, H1 2018
3.12 ARTES BIOTECHNOLOGY GMBH PIPELINE, H1 2018
3.13 COCRYSTAL PHARMA INC PIPELINE, H1 2018
3.14 CONATUS PHARMACEUTICALS INC PIPELINE, H1 2018
3.15 DEKK-TEC Inc PIPELINE, H1 2018
3.16 DEVELOPMENT CENTER FOR BIOTECHNOLOGY PIPELINE, H1 2018
3.17 DONGGUAN HEC TAIGEN BIOPHARMACEUTICALS PIPELINE, H1 2018
3.18 HEC PHARM CO LTD PIPELINE, H1 2018
3.19 F. HOFFMANN-LA ROCHE LTD PIPELINE, H1 2018
3.20 FORTUNEROCK (CHINA)CO., LTD PIPELINE, H1 2018
3.21 GALACTICA BIOTECH LIMITED PIPELINE, H1 2018
3.22 GILEAD SCIENCES, INC PIPELINE, H1 2018
3.23 SPRING BANK PHARMACEUTICALS, INC. PIPELINE, H1 2018
3.24 GINKGOPHARMA CO. LTD PIPELINE, H1 2018
3.25 GLAXOSMITHKLINE PHARMACEUTICALS LTD PIPELINE, H1 2018
3.26 REGULUS THERAPEUTICS INC PIPELINE, H1 2018
3.27 ADAPTIMMUNE THERAPEUTICS PLC PIPELINE, H1 2018
3.28 OKAIROS AG PIPELINE, H1 2018
3.29 IMMUNEMED, INC PIPELINE, H1 2018
3.30 INOVIO PHARMACEUTICALS INC PIPELINE, H1 2018
3.31 INTEGRATED BIOTHERAPEUTICS INC PIPELINE, H1 2018
3.32 IQUR LTD. PIPELINE, H1 2018
3.33 JN-INTERNATIONAL MEDICAL CORPORATION PIPELINE, H1 2018
3.34 ALIOS BIOPHARMA INC PIPELINE, H1 2018
3.35 ACHILLION PHARMACEUTICALS, INC.- PIPELINE, H1 2018
3.36 KARYOPHARM THERAPEUTICS INC PIPELINE, H1 2018
3.37 LIFEARC PIPELINE, H1 2018
3.38 LIGAND PHARMACEUTICALS INC PIPELINE, H1 2018
3.39 MEDIVIR AB PIPELINE, H1 2018
3.40 MERCK & COMPANY, INC PIPELINE, H1 2018
3.41 METALLOPHARM, LLC PIPELINE, H1 2018
3.42 MICROBIO CO., LTD PIPELINE, H1 2018
3.43 MULTICELL TECHNOLOGIES INC PIPELINE, H1 2018
3.44 MULTICELL TECHNOLOGIES INC PIPELINE, H1 2018
3.45 NOVALEX THERAPEUTICS INC PIPELINE, H1 2018
3.46 NOVATARG THERAPEUTICS, INC PIPELINE, H1 2018
3.47 NOVATARG THERAPEUTICS, INC PIPELINE, H1 2018
3.48 PRESIDIO PHARMACEUTICALS, INC. PIPELINE, H1 2018
3.49 RIBOSCIENCE LLC PIPELINE, H1 2018
3.50 RODOS BIOTARGET GMBH PIPELINE, H1 2018
3.51 SAVOY PHARMACEUTICALS, INC PIPELINE, H1 2018
3.52 SOMAGENICS INC PIPELINE, H1 2018
3.53 TAIGEN BIOTECHNOLOGY CO., LTD PIPELINE, H1 2018
3.54 THERAPURE BIOPHARMA, INC PIPELINE, H1 2018
3.55 THEVAX GENETICS VACCINE CO LTD PIPELINE, H1 2018
3.56 TREK THERAPEUTICS, PBC PIPELINE, H1 2018
3.57 VAKZINE PROJEKT MANAGEMENT GMBH PIPELINE, H1 2018
3.58 WHANIN PHARM CO.,LTD PIPELINE, H1 2018
3.59 TGV-LABORATORIES PIPELINE, H1 2018
4 HEPATITIS C DRUG SNAPSHOTS
4.1 E1-E2-NS5A VACCINE DETAILS
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.2 AV4025 DRUG DETAILS
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.3 AVR560 DRUG DETAILS
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.4 AMARNA VIRAL HEPATITIS DRUG DETAILS
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.5 ARABS-3 DRUG DETAILS
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.6 ARABS-4 DRUG DETAILS
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.7 ARABS-5 DRUG DETAILS
4.7.1 Snapshot
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.8 RAVIDASVIR DRUG DETAILS
4.8.1 Snapshot
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial Details
4.9 DANOPREVIR DRUG DETAILS
4.9.1 Snapshot
4.9.2 Drug Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
4.10 AT-527 DRUG DETAILS
4.10.1 Snapshot
4.10.2 Drug Overview
4.10.3 Mechanism of Action
4.10.4 Current Status
4.10.5 Trial Details
4.11 PEG-IFN-SA DRUG DETAILS
4.11.1 Snapshot
4.11.2 Drug Overview
4.11.3 Mechanism of Action
4.11.4 Current Status
4.12 KW 2 DRUG DETAILS
4.12.1 Snapshot
4.12.2 Drug Overview
4.12.3 Mechanism of Action
4.12.4 Current Status
4.13 KW 5 DRUG DETAILS
4.13.1 Snapshot
4.13.2 Drug Overview
4.13.3 Mechanism of Action
4.13.4 Current Status
4.14 NS5A INHIBITOR (Beta Pharma) DRUG DETAILS
4.14.1 Snapshot
4.14.2 Drug Overview
4.14.3 Mechanism of Action
4.14.4 Current Status
4.15 NS5B INHIBITOR (Biocad CJSC) DRUG DETAILS
4.15.1 Snapshot
4.15.2 Drug Overview
4.15.3 Mechanism of Action
4.15.4 Current Status
4.16 NS3 PROTEASE INHIBITOR (Biocad) DRUG DETAILS
4.16.1 Snapshot
4.16.2 Drug Overview
4.16.3 Mechanism of Action
4.16.4 Current Status
4.17 NS5A INHIBITOR (Biocad) DRUG DETAILS
4.17.1 Snapshot
4.17.2 Drug Overview
4.17.3 Mechanism of Action
4.17.4 Current Status
4.18 BIT 225 DRUG DETAILS
4.18.1 Snapshot
4.18.2 Drug Overview
4.18.3 Mechanism of Action
4.18.4 Current Status
4.19 BIT314 DRUG DETAILS
4.19.1 Snapshot
4.19.2 Drug Overview
4.19.3 Mechanism of Action
4.19.4 Current Status
4.20 BBT-012 DRUG DETAILS
4.20.1 Snapshot
4.20.2 Drug Overview
4.20.3 Mechanism of Action
4.20.4 Current Status
4.21 HCV VACCINE (ARTES/Burnet) DRUG DETAILS
4.21.1 Snapshot
4.21.2 Drug Overview
4.21.3 Mechanism of Action
4.21.4 Current Status
4.22 CC-31244 DRUG DETAILS
4.22.1 Snapshot
4.22.2 Drug Overview
4.22.3 Mechanism of Action
4.22.4 Current Status
4.23 CC-2850 DRUG DETAILS
4.23.1 Snapshot
4.23.2 Drug Overview
4.23.3 Mechanism of Action
4.23.4 Current Status
4.24 CC-2069 DRUG DETAILS
4.24.1 Snapshot
4.24.2 Drug Overview
4.24.3 Mechanism of Action
4.24.4 Current Status
4.25 EMRICASAN DRUG DETAILS
4.25.1 Snapshot
4.25.2 Drug Overview
4.25.3 Mechanism of Action
4.25.4 Current Status
4.26 IFN-Y FUSION PROTEINS DETAILS
4.26.1 Snapshot
4.26.2 Drug Overview
4.26.3 Mechanism of Action
4.26.4 Current Status
4.27 DCB-F1 DRUG DETAILS
4.27.1 Snapshot
4.27.2 Drug Overview
4.27.3 Mechanism of Action
4.27.4 Current Status
4.28 FURAPREVIR DRUG DETAILS
4.28.1 Snapshot
4.28.2 Drug Overview
4.28.3 Mechanism of Action
4.28.4 Current Status
4.29 YIMITASVIR DRUG DETAILS
4.29.1 Snapshot
4.29.2 Drug Overview
4.29.3 Mechanism of Action
4.29.4 Current Status
4.30 RITONAVIR-BOOSTED DANOPREVIR DRUG DETAILS
4.30.1 Snapshot
4.30.2 Drug Overview
4.30.3 Mechanism of Action
4.30.4 Current Status
4.31 MIRAVIRSEN DRUG DETAILS
4.31.1 Snapshot
4.31.2 Drug Overview
4.31.3 Mechanism of Action
4.31.4 Current Status
4.32 rHSA/IFN?2a DRUG DETAILS
4.32.1 Snapshot
4.32.2 Drug Overview
4.32.3 Mechanism of Action
4.32.4 Current Status
4.33 rHSA/IFN?2b DRUG DETAILS
4.33.1 Snapshot
4.33.2 Drug Overview
4.33.3 Mechanism of Action
4.33.4 Current Status
4.34 Small molecule for HCV (Galactica) DRUG DETAILS
4.34.1 Snapshot
4.34.2 Drug Overview
4.34.3 Mechanism of Action
4.34.4 Current Status
4.35 GS-9669 DRUG DETAILS
4.35.1 Snapshot
4.35.2 Drug Overview
4.35.3 Mechanism of Action
4.35.4 Current Status
4.36 GS-9857 DRUG DETAILS
4.36.1 Snapshot
4.36.2 Drug Overview
4.36.3 Mechanism of Action
4.36.4 Current Status
4.37 INARIGIVIR DRUG DETAILS
4.37.1 Snapshot
4.37.2 Drug Overview
4.37.3 Mechanism of Action
4.37.4 Current Status
4.38 NS3/4A INHIBITOR + NS5B INHIBITOR (GINKGO) DRUG DETAILS
4.38.1 Snapshot
4.38.2 Drug Overview
4.38.3 Mechanism of Action
4.38.4 Current Status
4.39 NS3/4A inhibitor + NS5A inhibitor (Ginkgo)DRUG DETAILS
4.39.1 Snapshot
4.39.2 Drug Overview
4.39.3 Mechanism of Action
4.39.4 Current Status
4.40 NS3/4A inhibitor + NS5B inhibitor + NS5A inhibitor (Ginkgo)DRUG DETAILS
4.40.1 Snapshot
4.40.2 Drug Overview
4.40.3 Mechanism of Action
4.40.4 Current Status
4.41 Seraprevir DRUG DETAILS
4.41.1 Snapshot
4.41.2 Drug Overview
4.41.3 Mechanism of Action
4.41.4 Current Status
4.42 GSK 2878175 DRUG DETAILS
4.42.1 Snapshot
4.42.2 Drug Overview
4.42.3 Mechanism of Action
4.42.4 Current Status
4.43 Hepatitis C+ Vaccine DRUG DETAILS
4.43.1 Snapshot
4.43.2 Drug Overview
4.43.3 Mechanism of Action
4.44 GSK2336805 DRUG DETAILS
4.44.1 Snapshot
4.44.2 Drug Overview
4.44.3 Mechanism of Action
4.44.4 Current Status
4.45 miR122 DRUG DETAILS
4.45.1 Snapshot
4.45.2 Drug Overview
4.45.3 Mechanism of Action
4.45.4 Current Status
4.46 AUTOLOGOUS T-cell THERAPIES DRUG DETAILS
4.46.1 Snapshot
4.46.2 Drug Overview
4.46.3 Mechanism of Action
4.46.4 Current Status
4.47 T CELL HCV VACCINE DETAILS
4.47.1 Snapshot
4.47.2 Drug Overview
4.47.3 Mechanism of Action
4.47.4 Current Status
4.48 Recombinant VSF DETAILS
4.48.1 Snapshot
4.48.2 Drug Overview
4.48.3 Mechanism of Action
4.48.4 Current Status
4.49 INO8000 DRUG DETAILS
4.49.1 Snapshot
4.49.2 Drug Overview
4.49.3 Mechanism of Action
4.49.4 Current Status
4.50 Hepatitis C Antibodies (Integrated Bio) DRUG DETAILS
4.50.1 Snapshot
4.50.2 Drug Overview
4.50.3 Mechanism of Action
4.50.4 Current Status
4.51 Hepatitis C vaccine (iQur) DRUG DETAILS
4.51.1 Snapshot
4.51.2 Drug Overview
4.51.3 Mechanism of Action
4.51.4 Current Status
4.52 Hepatitis C vaccine (JNIMC) DRUG DETAILS
4.52.1 Snapshot
4.52.2 Drug Overview
4.52.3 Mechanism of Action
4.52.4 Current Status
4.53 AL-335 DRUG DETAILS
4.53.1 Snapshot
4.53.2 Drug Overview
4.53.3 Mechanism of Action
4.53.4 Current Status
4.54 AL-516 DRUG DETAILS
4.54.1 Snapshot
4.54.2 Drug Overview
4.54.3 Mechanism of Action
4.54.4 Current Status
4.55 ACH-3102 DRUG DETAILS
4.55.1 Snapshot
4.55.2 Drug Overview
4.55.3 Mechanism of Action
4.55.4 Current Status
4.56 ACH-3422 DRUG DETAILS
4.56.1 Snapshot
4.56.2 Drug Overview
4.56.3 Mechanism of Action
4.56.4 Current Status
4.57 ACH-1625 DRUG DETAILS
4.57.1 Snapshot
4.57.2 Drug Overview
4.57.3 Mechanism of Action
4.57.4 Current Status
4.58 VERDINEXOR DRUG DETAILS
4.58.1 Snapshot
4.58.2 Drug Overview
4.58.3 Mechanism of Action
4.58.4 Current Status
4.59 HEPATITIS C ANTIBODY (LIFEARC) DRUG DETAILS
4.59.1 Snapshot
4.59.2 Drug Overview
4.59.3 Mechanism of Action
4.59.4 Current Status
4.60 NUC-101DRUG DETAILS
4.60.1 Snapshot
4.60.2 Drug Overview
4.60.3 Mechanism of Action
4.60.4 Current Status
4.61 MIV-802 DRUG DETAILS
4.61.1 Snapshot
4.61.2 Drug Overview
4.61.3 Mechanism of Action
4.61.4 Current Status
4.62 MBX 700 DRUG DETAILS
4.62.1 Snapshot
4.62.2 Drug Overview
4.62.3 Mechanism of Action
4.62.4 Current Status
4.63 Hepatitis C virus therapeutics (MetalloPharm) DRUG DETAILS
4.63.1 Snapshot
4.63.2 Drug Overview
4.63.3 Mechanism of Action
4.63.4 Current Status
4.64 MB-110 DRUG DETAILS
4.64.1 Snapshot
4.64.2 Drug Overview
4.64.3 Mechanism of Action
4.64.4 Current Status
4.65 MCT-465 DRUG DETAILS
4.65.1 Snapshot
4.65.2 Drug Overview
4.65.3 Mechanism of Action
4.65.4 Current Status
4.66 MCT-475 DRUG DETAILS
4.66.1 Snapshot
4.66.2 Drug Overview
4.66.3 Mechanism of Action
4.66.4 Current Status
4.67 Peglamda DRUG DETAILS
4.67.1 Snapshot
4.67.2 Drug Overview
4.67.3 Mechanism of Action
4.67.4 Current Status
4.68 Interferon alpha 2b biosimilar DRUG DETAILS
4.68.1 Snapshot
4.68.2 Drug Overview
4.68.3 Mechanism of Action
4.68.4 Current Status
4.69 HCV NS3/4A protease inhibitor (Novalex) DRUG DETAILS
4.69.1 Snapshot
4.69.2 Drug Overview
4.69.3 Mechanism of Action
4.69.4 Current Status
4.70 AMPK activators for hcv DRUG DETAILS
4.70.1 Snapshot
4.70.2 Drug Overview
4.70.3 Mechanism of Action
4.70.4 Current Status
4.71 Ropeginterferon alfa 2b DRUG DETAILS
4.71.1 Snapshot
4.71.2 Drug Overview
4.71.3 Mechanism of Action
4.71.4 Current Status
4.72 PPI 383 DRUG DETAILS
4.72.1 Snapshot
4.72.2 Drug Overview
4.72.3 Mechanism of Action
4.72.4 Current Status
4.73 Ravidasvir Hydrochloride DRUG DETAILS
4.73.1 Snapshot
4.73.2 Drug Overview
4.73.3 Mechanism of Action
4.73.4 Current Status
4.74 RBS-1154 and RBS 1049 DRUG DETAILS
4.74.1 Snapshot
4.74.2 Drug Overview
4.74.3 Mechanism of Action
4.74.4 Current Status
4.75 RBT05 DRUG DETAILS
4.75.1 Snapshot
4.75.2 Drug Overview
4.75.3 Mechanism of Action
4.75.4 Current Status
4.76 Viroprev DRUG DETAILS
4.76.1 Snapshot
4.76.2 Drug Overview
4.76.3 Mechanism of Action
4.76.4 Current Status
4.77 RNAi therapeutics DETAILS
4.77.1 Snapshot
4.77.2 Drug Overview
4.77.3 Mechanism of Action
4.77.4 Current Status
4.78 TG-2349 DRUG DETAILS
4.78.1 Snapshot
4.78.2 Drug Overview
4.78.3 Mechanism of Action
4.78.4 Current Status
4.79 JKB 122 DRUG DETAILS
4.79.1 Snapshot
4.79.2 Drug Overview
4.79.3 Mechanism of Action
4.79.4 Current Status
4.80 TBI 301 DRUG DETAILS
4.80.1 Snapshot
4.80.2 Drug Overview
4.80.3 Mechanism of Action
4.80.4 Current Status
4.81 TVGV-HC DRUG DETAILS
4.81.1 Snapshot
4.81.2 Drug Overview
4.81.3 Mechanism of Action
4.81.4 Current Status
4.82 TD-6450 DRUG DETAILS
4.82.1 Snapshot
4.82.2 Drug Overview
4.82.3 Mechanism of Action
4.82.4 Current Status
4.83 Soluferon DRUG DETAILS
4.83.1 Snapshot
4.83.2 Drug Overview
4.83.3 Mechanism of Action
4.83.4 Current Status
4.84 HCV (WhanIn) DRUG DETAILS
4.84.1 Snapshot
4.84.2 Drug Overview
4.84.3 Mechanism of Action
4.84.4 Current Status
4.85 Hep-1732 DRUG DETAILS
4.85.1 Snapshot
4.85.2 Drug Overview
4.85.3 Mechanism of Action
4.85.4 Current Status
5 RECENT DEVELOPMENTS IN HEPATITIS C PIPELINE
5.1 DAAs considered potential against HCV in older citizens
5.2 Egypt focusing on eliminating HCV from the country
5.3 New mathematical model analyzes HCV development in detail
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 HEPATITIS C- COMPANY WISE PIPELINE ANALYSIS
3.1 AKSHAYA BIO INC. PIPELINE, H1 2018
3.2 ALLACHEM, LLC PIPELINE, H1 2018
3.3 AMARNA THERAPEUTICS BV PIPELINE, H1 2018
3.4 ARA HEALTHCARE PVT LTD PIPELINE, H1 2018
3.5 ASCLETIS, INC PIPELINE, H1 2018
3.6 ATEA PHARMACEUTICALS, INC PIPELINE, H1 2018
3.7 BEIJING KAWIN TECHNOLOGY PIPELINE, H1 2018
3.8 BETA PHARMA, INC PIPELINE, H1 2018
3.9 BIOCAD CJSC PIPELINE, H1 2018
3.10 BIOTRON LIMITED PIPELINE, H1 2018
3.11 BOLDER BIOTECHNOLOGY, INC PIPELINE, H1 2018
3.12 ARTES BIOTECHNOLOGY GMBH PIPELINE, H1 2018
3.13 COCRYSTAL PHARMA INC PIPELINE, H1 2018
3.14 CONATUS PHARMACEUTICALS INC PIPELINE, H1 2018
3.15 DEKK-TEC Inc PIPELINE, H1 2018
3.16 DEVELOPMENT CENTER FOR BIOTECHNOLOGY PIPELINE, H1 2018
3.17 DONGGUAN HEC TAIGEN BIOPHARMACEUTICALS PIPELINE, H1 2018
3.18 HEC PHARM CO LTD PIPELINE, H1 2018
3.19 F. HOFFMANN-LA ROCHE LTD PIPELINE, H1 2018
3.20 FORTUNEROCK (CHINA)CO., LTD PIPELINE, H1 2018
3.21 GALACTICA BIOTECH LIMITED PIPELINE, H1 2018
3.22 GILEAD SCIENCES, INC PIPELINE, H1 2018
3.23 SPRING BANK PHARMACEUTICALS, INC. PIPELINE, H1 2018
3.24 GINKGOPHARMA CO. LTD PIPELINE, H1 2018
3.25 GLAXOSMITHKLINE PHARMACEUTICALS LTD PIPELINE, H1 2018
3.26 REGULUS THERAPEUTICS INC PIPELINE, H1 2018
3.27 ADAPTIMMUNE THERAPEUTICS PLC PIPELINE, H1 2018
3.28 OKAIROS AG PIPELINE, H1 2018
3.29 IMMUNEMED, INC PIPELINE, H1 2018
3.30 INOVIO PHARMACEUTICALS INC PIPELINE, H1 2018
3.31 INTEGRATED BIOTHERAPEUTICS INC PIPELINE, H1 2018
3.32 IQUR LTD. PIPELINE, H1 2018
3.33 JN-INTERNATIONAL MEDICAL CORPORATION PIPELINE, H1 2018
3.34 ALIOS BIOPHARMA INC PIPELINE, H1 2018
3.35 ACHILLION PHARMACEUTICALS, INC.- PIPELINE, H1 2018
3.36 KARYOPHARM THERAPEUTICS INC PIPELINE, H1 2018
3.37 LIFEARC PIPELINE, H1 2018
3.38 LIGAND PHARMACEUTICALS INC PIPELINE, H1 2018
3.39 MEDIVIR AB PIPELINE, H1 2018
3.40 MERCK & COMPANY, INC PIPELINE, H1 2018
3.41 METALLOPHARM, LLC PIPELINE, H1 2018
3.42 MICROBIO CO., LTD PIPELINE, H1 2018
3.43 MULTICELL TECHNOLOGIES INC PIPELINE, H1 2018
3.44 MULTICELL TECHNOLOGIES INC PIPELINE, H1 2018
3.45 NOVALEX THERAPEUTICS INC PIPELINE, H1 2018
3.46 NOVATARG THERAPEUTICS, INC PIPELINE, H1 2018
3.47 NOVATARG THERAPEUTICS, INC PIPELINE, H1 2018
3.48 PRESIDIO PHARMACEUTICALS, INC. PIPELINE, H1 2018
3.49 RIBOSCIENCE LLC PIPELINE, H1 2018
3.50 RODOS BIOTARGET GMBH PIPELINE, H1 2018
3.51 SAVOY PHARMACEUTICALS, INC PIPELINE, H1 2018
3.52 SOMAGENICS INC PIPELINE, H1 2018
3.53 TAIGEN BIOTECHNOLOGY CO., LTD PIPELINE, H1 2018
3.54 THERAPURE BIOPHARMA, INC PIPELINE, H1 2018
3.55 THEVAX GENETICS VACCINE CO LTD PIPELINE, H1 2018
3.56 TREK THERAPEUTICS, PBC PIPELINE, H1 2018
3.57 VAKZINE PROJEKT MANAGEMENT GMBH PIPELINE, H1 2018
3.58 WHANIN PHARM CO.,LTD PIPELINE, H1 2018
3.59 TGV-LABORATORIES PIPELINE, H1 2018
4 HEPATITIS C DRUG SNAPSHOTS
4.1 E1-E2-NS5A VACCINE DETAILS
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.2 AV4025 DRUG DETAILS
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.3 AVR560 DRUG DETAILS
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.4 AMARNA VIRAL HEPATITIS DRUG DETAILS
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.5 ARABS-3 DRUG DETAILS
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.6 ARABS-4 DRUG DETAILS
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.7 ARABS-5 DRUG DETAILS
4.7.1 Snapshot
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.8 RAVIDASVIR DRUG DETAILS
4.8.1 Snapshot
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial Details
4.9 DANOPREVIR DRUG DETAILS
4.9.1 Snapshot
4.9.2 Drug Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
4.10 AT-527 DRUG DETAILS
4.10.1 Snapshot
4.10.2 Drug Overview
4.10.3 Mechanism of Action
4.10.4 Current Status
4.10.5 Trial Details
4.11 PEG-IFN-SA DRUG DETAILS
4.11.1 Snapshot
4.11.2 Drug Overview
4.11.3 Mechanism of Action
4.11.4 Current Status
4.12 KW 2 DRUG DETAILS
4.12.1 Snapshot
4.12.2 Drug Overview
4.12.3 Mechanism of Action
4.12.4 Current Status
4.13 KW 5 DRUG DETAILS
4.13.1 Snapshot
4.13.2 Drug Overview
4.13.3 Mechanism of Action
4.13.4 Current Status
4.14 NS5A INHIBITOR (Beta Pharma) DRUG DETAILS
4.14.1 Snapshot
4.14.2 Drug Overview
4.14.3 Mechanism of Action
4.14.4 Current Status
4.15 NS5B INHIBITOR (Biocad CJSC) DRUG DETAILS
4.15.1 Snapshot
4.15.2 Drug Overview
4.15.3 Mechanism of Action
4.15.4 Current Status
4.16 NS3 PROTEASE INHIBITOR (Biocad) DRUG DETAILS
4.16.1 Snapshot
4.16.2 Drug Overview
4.16.3 Mechanism of Action
4.16.4 Current Status
4.17 NS5A INHIBITOR (Biocad) DRUG DETAILS
4.17.1 Snapshot
4.17.2 Drug Overview
4.17.3 Mechanism of Action
4.17.4 Current Status
4.18 BIT 225 DRUG DETAILS
4.18.1 Snapshot
4.18.2 Drug Overview
4.18.3 Mechanism of Action
4.18.4 Current Status
4.19 BIT314 DRUG DETAILS
4.19.1 Snapshot
4.19.2 Drug Overview
4.19.3 Mechanism of Action
4.19.4 Current Status
4.20 BBT-012 DRUG DETAILS
4.20.1 Snapshot
4.20.2 Drug Overview
4.20.3 Mechanism of Action
4.20.4 Current Status
4.21 HCV VACCINE (ARTES/Burnet) DRUG DETAILS
4.21.1 Snapshot
4.21.2 Drug Overview
4.21.3 Mechanism of Action
4.21.4 Current Status
4.22 CC-31244 DRUG DETAILS
4.22.1 Snapshot
4.22.2 Drug Overview
4.22.3 Mechanism of Action
4.22.4 Current Status
4.23 CC-2850 DRUG DETAILS
4.23.1 Snapshot
4.23.2 Drug Overview
4.23.3 Mechanism of Action
4.23.4 Current Status
4.24 CC-2069 DRUG DETAILS
4.24.1 Snapshot
4.24.2 Drug Overview
4.24.3 Mechanism of Action
4.24.4 Current Status
4.25 EMRICASAN DRUG DETAILS
4.25.1 Snapshot
4.25.2 Drug Overview
4.25.3 Mechanism of Action
4.25.4 Current Status
4.26 IFN-Y FUSION PROTEINS DETAILS
4.26.1 Snapshot
4.26.2 Drug Overview
4.26.3 Mechanism of Action
4.26.4 Current Status
4.27 DCB-F1 DRUG DETAILS
4.27.1 Snapshot
4.27.2 Drug Overview
4.27.3 Mechanism of Action
4.27.4 Current Status
4.28 FURAPREVIR DRUG DETAILS
4.28.1 Snapshot
4.28.2 Drug Overview
4.28.3 Mechanism of Action
4.28.4 Current Status
4.29 YIMITASVIR DRUG DETAILS
4.29.1 Snapshot
4.29.2 Drug Overview
4.29.3 Mechanism of Action
4.29.4 Current Status
4.30 RITONAVIR-BOOSTED DANOPREVIR DRUG DETAILS
4.30.1 Snapshot
4.30.2 Drug Overview
4.30.3 Mechanism of Action
4.30.4 Current Status
4.31 MIRAVIRSEN DRUG DETAILS
4.31.1 Snapshot
4.31.2 Drug Overview
4.31.3 Mechanism of Action
4.31.4 Current Status
4.32 rHSA/IFN?2a DRUG DETAILS
4.32.1 Snapshot
4.32.2 Drug Overview
4.32.3 Mechanism of Action
4.32.4 Current Status
4.33 rHSA/IFN?2b DRUG DETAILS
4.33.1 Snapshot
4.33.2 Drug Overview
4.33.3 Mechanism of Action
4.33.4 Current Status
4.34 Small molecule for HCV (Galactica) DRUG DETAILS
4.34.1 Snapshot
4.34.2 Drug Overview
4.34.3 Mechanism of Action
4.34.4 Current Status
4.35 GS-9669 DRUG DETAILS
4.35.1 Snapshot
4.35.2 Drug Overview
4.35.3 Mechanism of Action
4.35.4 Current Status
4.36 GS-9857 DRUG DETAILS
4.36.1 Snapshot
4.36.2 Drug Overview
4.36.3 Mechanism of Action
4.36.4 Current Status
4.37 INARIGIVIR DRUG DETAILS
4.37.1 Snapshot
4.37.2 Drug Overview
4.37.3 Mechanism of Action
4.37.4 Current Status
4.38 NS3/4A INHIBITOR + NS5B INHIBITOR (GINKGO) DRUG DETAILS
4.38.1 Snapshot
4.38.2 Drug Overview
4.38.3 Mechanism of Action
4.38.4 Current Status
4.39 NS3/4A inhibitor + NS5A inhibitor (Ginkgo)DRUG DETAILS
4.39.1 Snapshot
4.39.2 Drug Overview
4.39.3 Mechanism of Action
4.39.4 Current Status
4.40 NS3/4A inhibitor + NS5B inhibitor + NS5A inhibitor (Ginkgo)DRUG DETAILS
4.40.1 Snapshot
4.40.2 Drug Overview
4.40.3 Mechanism of Action
4.40.4 Current Status
4.41 Seraprevir DRUG DETAILS
4.41.1 Snapshot
4.41.2 Drug Overview
4.41.3 Mechanism of Action
4.41.4 Current Status
4.42 GSK 2878175 DRUG DETAILS
4.42.1 Snapshot
4.42.2 Drug Overview
4.42.3 Mechanism of Action
4.42.4 Current Status
4.43 Hepatitis C+ Vaccine DRUG DETAILS
4.43.1 Snapshot
4.43.2 Drug Overview
4.43.3 Mechanism of Action
4.44 GSK2336805 DRUG DETAILS
4.44.1 Snapshot
4.44.2 Drug Overview
4.44.3 Mechanism of Action
4.44.4 Current Status
4.45 miR122 DRUG DETAILS
4.45.1 Snapshot
4.45.2 Drug Overview
4.45.3 Mechanism of Action
4.45.4 Current Status
4.46 AUTOLOGOUS T-cell THERAPIES DRUG DETAILS
4.46.1 Snapshot
4.46.2 Drug Overview
4.46.3 Mechanism of Action
4.46.4 Current Status
4.47 T CELL HCV VACCINE DETAILS
4.47.1 Snapshot
4.47.2 Drug Overview
4.47.3 Mechanism of Action
4.47.4 Current Status
4.48 Recombinant VSF DETAILS
4.48.1 Snapshot
4.48.2 Drug Overview
4.48.3 Mechanism of Action
4.48.4 Current Status
4.49 INO8000 DRUG DETAILS
4.49.1 Snapshot
4.49.2 Drug Overview
4.49.3 Mechanism of Action
4.49.4 Current Status
4.50 Hepatitis C Antibodies (Integrated Bio) DRUG DETAILS
4.50.1 Snapshot
4.50.2 Drug Overview
4.50.3 Mechanism of Action
4.50.4 Current Status
4.51 Hepatitis C vaccine (iQur) DRUG DETAILS
4.51.1 Snapshot
4.51.2 Drug Overview
4.51.3 Mechanism of Action
4.51.4 Current Status
4.52 Hepatitis C vaccine (JNIMC) DRUG DETAILS
4.52.1 Snapshot
4.52.2 Drug Overview
4.52.3 Mechanism of Action
4.52.4 Current Status
4.53 AL-335 DRUG DETAILS
4.53.1 Snapshot
4.53.2 Drug Overview
4.53.3 Mechanism of Action
4.53.4 Current Status
4.54 AL-516 DRUG DETAILS
4.54.1 Snapshot
4.54.2 Drug Overview
4.54.3 Mechanism of Action
4.54.4 Current Status
4.55 ACH-3102 DRUG DETAILS
4.55.1 Snapshot
4.55.2 Drug Overview
4.55.3 Mechanism of Action
4.55.4 Current Status
4.56 ACH-3422 DRUG DETAILS
4.56.1 Snapshot
4.56.2 Drug Overview
4.56.3 Mechanism of Action
4.56.4 Current Status
4.57 ACH-1625 DRUG DETAILS
4.57.1 Snapshot
4.57.2 Drug Overview
4.57.3 Mechanism of Action
4.57.4 Current Status
4.58 VERDINEXOR DRUG DETAILS
4.58.1 Snapshot
4.58.2 Drug Overview
4.58.3 Mechanism of Action
4.58.4 Current Status
4.59 HEPATITIS C ANTIBODY (LIFEARC) DRUG DETAILS
4.59.1 Snapshot
4.59.2 Drug Overview
4.59.3 Mechanism of Action
4.59.4 Current Status
4.60 NUC-101DRUG DETAILS
4.60.1 Snapshot
4.60.2 Drug Overview
4.60.3 Mechanism of Action
4.60.4 Current Status
4.61 MIV-802 DRUG DETAILS
4.61.1 Snapshot
4.61.2 Drug Overview
4.61.3 Mechanism of Action
4.61.4 Current Status
4.62 MBX 700 DRUG DETAILS
4.62.1 Snapshot
4.62.2 Drug Overview
4.62.3 Mechanism of Action
4.62.4 Current Status
4.63 Hepatitis C virus therapeutics (MetalloPharm) DRUG DETAILS
4.63.1 Snapshot
4.63.2 Drug Overview
4.63.3 Mechanism of Action
4.63.4 Current Status
4.64 MB-110 DRUG DETAILS
4.64.1 Snapshot
4.64.2 Drug Overview
4.64.3 Mechanism of Action
4.64.4 Current Status
4.65 MCT-465 DRUG DETAILS
4.65.1 Snapshot
4.65.2 Drug Overview
4.65.3 Mechanism of Action
4.65.4 Current Status
4.66 MCT-475 DRUG DETAILS
4.66.1 Snapshot
4.66.2 Drug Overview
4.66.3 Mechanism of Action
4.66.4 Current Status
4.67 Peglamda DRUG DETAILS
4.67.1 Snapshot
4.67.2 Drug Overview
4.67.3 Mechanism of Action
4.67.4 Current Status
4.68 Interferon alpha 2b biosimilar DRUG DETAILS
4.68.1 Snapshot
4.68.2 Drug Overview
4.68.3 Mechanism of Action
4.68.4 Current Status
4.69 HCV NS3/4A protease inhibitor (Novalex) DRUG DETAILS
4.69.1 Snapshot
4.69.2 Drug Overview
4.69.3 Mechanism of Action
4.69.4 Current Status
4.70 AMPK activators for hcv DRUG DETAILS
4.70.1 Snapshot
4.70.2 Drug Overview
4.70.3 Mechanism of Action
4.70.4 Current Status
4.71 Ropeginterferon alfa 2b DRUG DETAILS
4.71.1 Snapshot
4.71.2 Drug Overview
4.71.3 Mechanism of Action
4.71.4 Current Status
4.72 PPI 383 DRUG DETAILS
4.72.1 Snapshot
4.72.2 Drug Overview
4.72.3 Mechanism of Action
4.72.4 Current Status
4.73 Ravidasvir Hydrochloride DRUG DETAILS
4.73.1 Snapshot
4.73.2 Drug Overview
4.73.3 Mechanism of Action
4.73.4 Current Status
4.74 RBS-1154 and RBS 1049 DRUG DETAILS
4.74.1 Snapshot
4.74.2 Drug Overview
4.74.3 Mechanism of Action
4.74.4 Current Status
4.75 RBT05 DRUG DETAILS
4.75.1 Snapshot
4.75.2 Drug Overview
4.75.3 Mechanism of Action
4.75.4 Current Status
4.76 Viroprev DRUG DETAILS
4.76.1 Snapshot
4.76.2 Drug Overview
4.76.3 Mechanism of Action
4.76.4 Current Status
4.77 RNAi therapeutics DETAILS
4.77.1 Snapshot
4.77.2 Drug Overview
4.77.3 Mechanism of Action
4.77.4 Current Status
4.78 TG-2349 DRUG DETAILS
4.78.1 Snapshot
4.78.2 Drug Overview
4.78.3 Mechanism of Action
4.78.4 Current Status
4.79 JKB 122 DRUG DETAILS
4.79.1 Snapshot
4.79.2 Drug Overview
4.79.3 Mechanism of Action
4.79.4 Current Status
4.80 TBI 301 DRUG DETAILS
4.80.1 Snapshot
4.80.2 Drug Overview
4.80.3 Mechanism of Action
4.80.4 Current Status
4.81 TVGV-HC DRUG DETAILS
4.81.1 Snapshot
4.81.2 Drug Overview
4.81.3 Mechanism of Action
4.81.4 Current Status
4.82 TD-6450 DRUG DETAILS
4.82.1 Snapshot
4.82.2 Drug Overview
4.82.3 Mechanism of Action
4.82.4 Current Status
4.83 Soluferon DRUG DETAILS
4.83.1 Snapshot
4.83.2 Drug Overview
4.83.3 Mechanism of Action
4.83.4 Current Status
4.84 HCV (WhanIn) DRUG DETAILS
4.84.1 Snapshot
4.84.2 Drug Overview
4.84.3 Mechanism of Action
4.84.4 Current Status
4.85 Hep-1732 DRUG DETAILS
4.85.1 Snapshot
4.85.2 Drug Overview
4.85.3 Mechanism of Action
4.85.4 Current Status
5 RECENT DEVELOPMENTS IN HEPATITIS C PIPELINE
5.1 DAAs considered potential against HCV in older citizens
5.2 Egypt focusing on eliminating HCV from the country
5.3 New mathematical model analyzes HCV development in detail
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
LIST OF FIGURES
Figure 1: Hepatitis C Pipeline by Phase, H1- 2018
Figure 2: Hepatitis C Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Hepatitis C Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
Figure 1: Hepatitis C Pipeline by Phase, H1- 2018
Figure 2: Hepatitis C Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Hepatitis C Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Hepatitis C Pipeline by Phase, H1- 2018
Table 2: Hepatitis C Pipeline by Companies, H1- 2018
Table 3: Hepatitis C Pipeline by Mechanism of Action, H1- 2018
Table 4: Akshaya Bio Inc.- Hepatitis C Pipeline, H1- 2018
Table 5: AllaChem, LLC - Hepatitis C Pipeline, H1- 2018
Table 6: Amarna Therapeutics BV - Hepatitis C Pipeline, H1- 2018
Table 7: ARA Healthcare Pvt Ltd - Hepatitis C Pipeline, H1- 2018
Table 8: Ascletis, Inc - Hepatitis C Pipeline, H1- 2018
Table 9: Atea Pharmaceuticals, Inc - Hepatitis C Pipeline, H1- 2018
Table 10: Beijing Kawin Technology Share-Holding Co., Ltd.- Hepatitis C Pipeline, H1- 2018
Table 11: Beta Pharma, Inc.- Hepatitis C Pipeline, H1- 2018
Table 12: Biocad CJSC - Hepatitis C Pipeline, H1- 2018
Table 13: Biotron Limited - Hepatitis C Pipeline, H1- 2018
Table 14: Bolder BioTechnology, Inc - Hepatitis C Pipeline, H1- 2018
Table 15: ARTES Biotechnology GmbH - Hepatitis C Pipeline, H1- 2018
Table 16: Cocrystal Pharma Inc - Hepatitis C Pipeline, H1- 2018
Table 17: Conatus Pharmaceuticals Inc - Hepatitis C Pipeline, H1- 2018
Table 18: DEKK-TEC Inc - Hepatitis C Pipeline, H1- 2018
Table 19: Development Center for Biotechnology - Hepatitis C Pipeline, H1- 2018
Table 20: Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd - Hepatitis C Pipeline, H1- 2018
Table 21: HEC Pharm Co Ltd - Hepatitis C Pipeline, H1- 2018
Table 22: F. Hoffmann-La Roche Ltd - Hepatitis C Pipeline, H1- 2018
Table 23: FortuneRock(China)Co., Ltd.- Hepatitis C Pipeline, H1- 2018
Table 24: Galactica Biotech Limited - Hepatitis C Pipeline, H1- 2018
Table 25: Gilead Sciences, Inc.- Hepatitis C Pipeline, H1- 2018
Table 26: Spring Bank Pharmaceuticals, Inc.- Hepatitis C Pipeline, H1- 2018
Table 27: GinkgoPharma Co. Ltd - Hepatitis C Pipeline, H1- 2018
Table 28: GlaxoSmithKline Pharmaceuticals Ltd - Hepatitis C Pipeline, H1- 2018
Table 29: Regulus Therapeutics Inc - Hepatitis C Pipeline, H1- 2018
Table 30: Adaptimmune Therapeutics plc - Hepatitis C Pipeline, H1- 2018
Table 31: Okairos AG - Hepatitis C Pipeline, H1- 2018
Table 32: ImmuneMed, Inc. - Hepatitis C Pipeline, H1- 2018
Table 33: Inovio Pharmaceuticals Inc - Hepatitis C Pipeline, H1- 2018
Table 34: Integrated Biotherapeutics Inc.- Hepatitis C Pipeline, H1- 2018
Table 35: iQur Ltd.- Hepatitis C Pipeline, H1- 2018
Table 36: JN-International Medical Corporation - Hepatitis C Pipeline, H1- 2018
Table 37: Alios BioPharma Inc.- Hepatitis C Pipeline, H1- 2018
Table 38: Achillion Pharmaceuticals, Inc.- Hepatitis C Pipeline, H1- 2018
Table 39: Karyopharm Therapeutics Inc - Hepatitis C Pipeline, H1- 2018
Table 40: LifeArc - Hepatitis C Pipeline, H1- 2018
Table 41: Ligand Pharmaceuticals Inc - Hepatitis C Pipeline, H1- 2018
Table 42: Medivir AB - Hepatitis C Pipeline, H1- 2018
Table 43: Merck & Company, Inc.- Hepatitis C Pipeline, H1- 2018
Table 44: Metallopharm, LLC - Hepatitis C Pipeline, H1- 2018
Table 45: Microbio Co., Ltd. Hepatitis C Pipeline, H1- 2018
Table 46: MultiCell Technologies Inc Hepatitis C Pipeline, H1- 2018
Table 47: MultiCell Technologies Inc Hepatitis C Pipeline, H1- 2018
Table 48: Novalex Therapeutics Inc Hepatitis C Pipeline, H1- 2018
Table 49: NovaTarg Therapeutics, Inc Hepatitis C Pipeline, H1- 2018
Table 50: NovaTarg Therapeutics, Inc Hepatitis C Pipeline, H1- 2018
Table 51: Presidio Pharmaceuticals, Inc. Hepatitis C Pipeline, H1- 2018
Table 52: Riboscience LLC Hepatitis C Pipeline, H1- 2018
Table 53: Rodos BioTarget GmbH Hepatitis C Pipeline, H1- 2018
Table 54: Savoy Pharmaceuticals, Inc Hepatitis C Pipeline, H1- 2018
Table 55: SomaGenics Inc Hepatitis C Pipeline, H1- 2018
Table 56: TaiGen Biotechnology Co., Ltd. Hepatitis C Pipeline, H1- 2018
Table 57: Therapure BioPharma, Inc Hepatitis C Pipeline, H1- 2018
Table 58: Thevax Genetics Vaccine Co Ltd Hepatitis C Pipeline, H1- 2018
Table 59: Trek Therapeutics, PBC Hepatitis C Pipeline, H1- 2018
Table 60: Vakzine Projekt Management GmbH Hepatitis C Pipeline, H1- 2018
Table 61: WHANIN PHARM CO.,LTD Hepatitis C Pipeline, H1- 2018
Table 62: TGV-Laboratories Hepatitis C Pipeline, H1- 2018
Table 1: Hepatitis C Pipeline by Phase, H1- 2018
Table 2: Hepatitis C Pipeline by Companies, H1- 2018
Table 3: Hepatitis C Pipeline by Mechanism of Action, H1- 2018
Table 4: Akshaya Bio Inc.- Hepatitis C Pipeline, H1- 2018
Table 5: AllaChem, LLC - Hepatitis C Pipeline, H1- 2018
Table 6: Amarna Therapeutics BV - Hepatitis C Pipeline, H1- 2018
Table 7: ARA Healthcare Pvt Ltd - Hepatitis C Pipeline, H1- 2018
Table 8: Ascletis, Inc - Hepatitis C Pipeline, H1- 2018
Table 9: Atea Pharmaceuticals, Inc - Hepatitis C Pipeline, H1- 2018
Table 10: Beijing Kawin Technology Share-Holding Co., Ltd.- Hepatitis C Pipeline, H1- 2018
Table 11: Beta Pharma, Inc.- Hepatitis C Pipeline, H1- 2018
Table 12: Biocad CJSC - Hepatitis C Pipeline, H1- 2018
Table 13: Biotron Limited - Hepatitis C Pipeline, H1- 2018
Table 14: Bolder BioTechnology, Inc - Hepatitis C Pipeline, H1- 2018
Table 15: ARTES Biotechnology GmbH - Hepatitis C Pipeline, H1- 2018
Table 16: Cocrystal Pharma Inc - Hepatitis C Pipeline, H1- 2018
Table 17: Conatus Pharmaceuticals Inc - Hepatitis C Pipeline, H1- 2018
Table 18: DEKK-TEC Inc - Hepatitis C Pipeline, H1- 2018
Table 19: Development Center for Biotechnology - Hepatitis C Pipeline, H1- 2018
Table 20: Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd - Hepatitis C Pipeline, H1- 2018
Table 21: HEC Pharm Co Ltd - Hepatitis C Pipeline, H1- 2018
Table 22: F. Hoffmann-La Roche Ltd - Hepatitis C Pipeline, H1- 2018
Table 23: FortuneRock(China)Co., Ltd.- Hepatitis C Pipeline, H1- 2018
Table 24: Galactica Biotech Limited - Hepatitis C Pipeline, H1- 2018
Table 25: Gilead Sciences, Inc.- Hepatitis C Pipeline, H1- 2018
Table 26: Spring Bank Pharmaceuticals, Inc.- Hepatitis C Pipeline, H1- 2018
Table 27: GinkgoPharma Co. Ltd - Hepatitis C Pipeline, H1- 2018
Table 28: GlaxoSmithKline Pharmaceuticals Ltd - Hepatitis C Pipeline, H1- 2018
Table 29: Regulus Therapeutics Inc - Hepatitis C Pipeline, H1- 2018
Table 30: Adaptimmune Therapeutics plc - Hepatitis C Pipeline, H1- 2018
Table 31: Okairos AG - Hepatitis C Pipeline, H1- 2018
Table 32: ImmuneMed, Inc. - Hepatitis C Pipeline, H1- 2018
Table 33: Inovio Pharmaceuticals Inc - Hepatitis C Pipeline, H1- 2018
Table 34: Integrated Biotherapeutics Inc.- Hepatitis C Pipeline, H1- 2018
Table 35: iQur Ltd.- Hepatitis C Pipeline, H1- 2018
Table 36: JN-International Medical Corporation - Hepatitis C Pipeline, H1- 2018
Table 37: Alios BioPharma Inc.- Hepatitis C Pipeline, H1- 2018
Table 38: Achillion Pharmaceuticals, Inc.- Hepatitis C Pipeline, H1- 2018
Table 39: Karyopharm Therapeutics Inc - Hepatitis C Pipeline, H1- 2018
Table 40: LifeArc - Hepatitis C Pipeline, H1- 2018
Table 41: Ligand Pharmaceuticals Inc - Hepatitis C Pipeline, H1- 2018
Table 42: Medivir AB - Hepatitis C Pipeline, H1- 2018
Table 43: Merck & Company, Inc.- Hepatitis C Pipeline, H1- 2018
Table 44: Metallopharm, LLC - Hepatitis C Pipeline, H1- 2018
Table 45: Microbio Co., Ltd. Hepatitis C Pipeline, H1- 2018
Table 46: MultiCell Technologies Inc Hepatitis C Pipeline, H1- 2018
Table 47: MultiCell Technologies Inc Hepatitis C Pipeline, H1- 2018
Table 48: Novalex Therapeutics Inc Hepatitis C Pipeline, H1- 2018
Table 49: NovaTarg Therapeutics, Inc Hepatitis C Pipeline, H1- 2018
Table 50: NovaTarg Therapeutics, Inc Hepatitis C Pipeline, H1- 2018
Table 51: Presidio Pharmaceuticals, Inc. Hepatitis C Pipeline, H1- 2018
Table 52: Riboscience LLC Hepatitis C Pipeline, H1- 2018
Table 53: Rodos BioTarget GmbH Hepatitis C Pipeline, H1- 2018
Table 54: Savoy Pharmaceuticals, Inc Hepatitis C Pipeline, H1- 2018
Table 55: SomaGenics Inc Hepatitis C Pipeline, H1- 2018
Table 56: TaiGen Biotechnology Co., Ltd. Hepatitis C Pipeline, H1- 2018
Table 57: Therapure BioPharma, Inc Hepatitis C Pipeline, H1- 2018
Table 58: Thevax Genetics Vaccine Co Ltd Hepatitis C Pipeline, H1- 2018
Table 59: Trek Therapeutics, PBC Hepatitis C Pipeline, H1- 2018
Table 60: Vakzine Projekt Management GmbH Hepatitis C Pipeline, H1- 2018
Table 61: WHANIN PHARM CO.,LTD Hepatitis C Pipeline, H1- 2018
Table 62: TGV-Laboratories Hepatitis C Pipeline, H1- 2018
